Modern approach in the therapy of Alzheimer's disease
https://doi.org/10.24884/1607-4181-2014-21-1-6-10
Abstract
Alzheimer's disease is a well-known neurodegenerative disorder. One of its main risk factors is age. Due to a worldwide increase of human longevity Alzheimer's disease became the most common form of dementia. The disease has been studied in different countries for many decades but still its etiology remains unclear. By now there is no cure for Alzheimer's, moreover there are no that can at least slow down the disease progression. In this review we made an attempt to summarize all current studies of the most advanced drugs for Alzheimer's.
About the Authors
D. I. Rodin
НИЦ «Курчатовский институт» Петербургского института ядерной физики имени Б.П. Константинова; Институт экспериментальной медицины
Russian Federation
Russian Federation
A. L. Schvarzman
НИЦ «Курчатовский институт» Петербургского института ядерной физики имени Б.П. Константинова; Институт экспериментальной медицины
Russian Federation
Russian Federation
S. V. Saranzeva
НИЦ «Курчатовский институт» Петербургского института ядерной физики имени Б.П. Константинова; Институт экспериментальной медицины
Russian Federation
Russian Federation
References
1. Aisen P.S., Saumier D., Briand R. et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease // Neurology. - 2006. - Vol. 67. - P. 1757-1763.
2. Bard F. et al. Peripherally administered antibodies against amyloid в-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease // Nat. Med. -2000. - № 6. - Р. 916-919.
3. Becker R.E. & Greig H.H. Increasing the success rate for Alzheimer's disease drug discovery and development // Expert Opin. Drug Discov. - 2012. - № 4. - Р. 367-370.
4. Becker R.E. & Greig N.H. Why so few drugs for Alzheimer's disease? Are methods failing drugs? // Curr. Alzheimer Res. -2010. - № 7. - Р. 27-35.
5. Becker R.E., Greig H.H. & Giacobini E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? // J. Alzheimers Dis. - 2008. -№ 15. - Р. 303-325.
6. Beher D., Clarke E.E., Wrigley J.D. et al. Selected nonsteroidal anti-inflammatory drugs and their derivatives target g-secretase at a novel site: evidence for an allosteric mechanism // J. Biol. Chem. - 2004. - № 279. - Р. 43419-43426.
7. Blennow K. et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarkers levels in patients with mild to moderate Alzheimer disease // Arch. Neurol. - 2012. -№ 69. - Р. 1002- 1010.
8. Boche D., Denham N., Holmes C. & Nicoll J.A. Neuropathology after active Aв42 immunotherapy: implications for Alzheimer's disease pathogenesis // Acta Neuropathol. - 2010. -№ 120. - Р. 369-384.
9. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories // Neurobiol. Aging. - 1997. - № 18 (4). - Р. 351-357.
10. Brookmeyer R. et al., Forecasting the global burden of Alzheimer's disease // Alzheimers Dement. - 2007. - № 3 (3). -Р. 186-191.
11. Business Wire. Pfizer announces topline results of first of four studies in bapineuzumab phase 3 program. Business Wire. URL: http://www.businesswire.com/news/home/20120723006412/en/Pfizer-Announces-Topline-Results-Studies-Bapineuzumab-Phase (2012).
12. Choi Y.H., Yon G.H., Hong K.S. et al. In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia // Planta Med. - 2008. - Vol. 74. - P. 1405-1408.
13. Citron M. Strategies for disease modification in Alzheimer's disease // Nature Rev. Neuroscie. - 2004. - Vol. 5. -P. 677-685.
14. Dodel R. et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomized, double-blind, placebo-controlled, dose-finding trial // Lancet Neurol. - 2013. - № 12. - Р. 233-243.
15. Doody R.S. Therapeutic standards in Alzheimer disease // Alzheimer Dis. Assoc. Disord. - 1999. - Vol. 13. - Suppl. -P. 20-26.
16. Eli Lilly and Company. Lilly announces detailed results of phase 3 Solanezumab EXPEDITIONS studies following a presentation of the independent analyses by the Alzheimer's Disease Cooperative Study (ADCS) // Eli Lilly and Company. URL: http://newsroom.lilly.com/releasedetail.cfm?releaseid=711933 (2012).
17. Eli Lilly and Company. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials // Eli Lilly and Company. URL: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=499794 (2010).
18. Ferreira S.T. & Klein W.L. The Aв oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease // Neurobiol. Learn. Mem. - 2011. - № 96. - Р. 529-543.
19. Ferris S.H. Evaluation of memantine for the treatment of Alzheimer's disease // Expert Opin. Pharmacother. - 2003. -Vol. 4. - P. 2305-2313.
20. Galimberti D., Fenoglio C. and Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? // Curr. Aging. Sci. - 2008. - № 1. - Р. 30-41.
21. Gelinas D.S., DaSilva K., Fenili D. et al. Immunotherapy for Alzheimer's disease // Proc. Natl. Acad. Sci. USA. - 2004. -Vol. 101. - Suppl. 2. - P. 4657-4662.
22. Giacobini E. & Becker R.E. One hundred years after discovery of Alzheimer's disease. A turning point for therapy? // J. Alzheimers. Dis. - 2007. - № 12. - Р. 37-52.
23. Gilman S., Koller M., Black R.S. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial // Neurology. - 2005. - Vol. 64. - P. 1553- 1562.
24. Goedert M., Spillantini M. A century of Alzheimer's disease // Neurobiol. Aging. - 1997. - № 18 (4). - Р. 351-357.
25. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. An updated summary of the amyloid hypothesis // Science. -2002. - Vol. 297. - P. 353-356.
26. Hardy J.A. & Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis // Science. - 1992. - № 256. -Р. 184- 185.
27. Hardy J. Alzheimer disease: the amyloid cascade hypothesis: an update and reappraisal // J. Alzheimers. Dis. - 2006. -№ 9. - Р. 151-153.
28. Hardy J. Testing times for the «amyloid cascade hypothesis» // Neurobiol. Aging. - 2002. - № 6. - Р. 1073-1074.
29. Henley D.B., May P.C., Dean R.A. & Siemers E.R. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease // Exp. Opin. Pharmacother. - 2009. - № 10. - Р. 1657-1674.
30. Huang W., Yu H., Sheng R., Li J., Hu Y. Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors // Bioorg. Med. Chem. - 2008. -Vol. 16. - P. 10190-10197.
31. Iwata N., Tsubuki M., Takaki Y. et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition // Nature Med. - 2000. - Vol. 6. - P. 143- 150.
32. Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form // Neuroscie Let. - 2003. - Vol. 350. - P. 113-116.
33. Kukar T., Prescott S., Eriksen J.L. et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice // BMC Neurosci. - 2007. - № 8. - Р. 54.
34. Lannfelt L. et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aв as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial // Lancet Neurol. - 2008. - № 9. - Р. 779-786.
35. Laras Y., Garino C., Dessolin J. et al. New N(4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors // J. Enzyme Inhib. Med. Chem. - 2009. - Vol. 24. - P. 181-187.
36. Leung D., Abbenante G., Fairlie D.P. Protease inhibitors: current status and future prospects // J. Med. Chem. -2000. - Vol. 43. - P. 305-341.
37. Marcade M., Bourdin J., Loiseau N. et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing // J. Neurochem. - 2008. - № 106. - Р. 392-404.
38. Mayeux R., Stern Y. Epidemiology of Alzheimer disease // Cold Spring. Harb. Perspect. Med. - 2012. - № 2 (8).
39. Mullane K. & Williams M. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond? // Biochem. Pharmacol. -2013. - № 85. - Р. 289-305.
40. Muller U.C., Zheng H. Physiological functions of APP family proteins // Cold Spring Harb Perspect Med. - 2012. -№ 2 (2). - Р. a006288.
41. Nussbaum R., Ellis C. Alzheimer's disease and Parkinson's disease // N. Engl. J. Med. - 2003. - № 348 (14). - Р. 1356-1364.
42. Prince M., Prina M., Guerchet M. World Alzheimer Report 2013. Journey of Caring An analysis of long-term care for dementia. URL: http://www.alz.co.uk/research/world-report-2013.
43. Reddy V.P., Zhu X., Perry G. and Smith M.A. Oxidative stress in diabetes and Alzheimer's disease // J. Alzheimers. Dis. - 2009. - № 16. - Р. 763-774.
44. Relkin N. et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease // Neurobiol. Aging. - 2009. - № 30 (11). - Р. 1728-1736.
45. Salloway S. et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer Disease // Neurology. - 2011. - № 77. - Р. 1253-1262.
46. Samuels S., Davis K. Experimental approaches to cognitive disturbance in Alzheimer's disease // Harv. Rev. Psychiatry. -1998. - № 6 (1). - Р. 11-22.
47. Sarantseva S., Timoshenko S., Bolshakova O. et al. Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease // PLOS One. - 2009. - № 7 (4). -Р. e8191.
48. Saura C.A., Choi S.-Y., Beglopoulos V. et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration // Neuron. - 2004. - Vol. 42. - P. 23-36.
49. Schenk D., Barbour R., Dunn W. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in PDAPP mouse // Nature. - 1999. - Vol. 400. - P. 173-177.
50. Shimmyo Y., Kihara T., Akaike A. et al. Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced betasite APP cleaving enzyme-1 upregulation // Neuroreport. -2008. - Vol. 19. - P. 1329-1333.
51. Stefani M. and Liguri G. Cholesterol in Alzheimer's disease: unresolved questions // Curr. Alzheimer. Res. - 2009. - № 6. -Р. 15-29.
52. Townsend M., Cleary J.P., Mehta T. et al. Orally available compound prevents deficits in memory caused by the Alzheimer Amyloid-b oligomers // Ann. Neurol. - 2006. - Vol. 60. -P. 668-676.
53. Townsend K.P. and Pratico D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs // FASEB J. - 2005. - № 19. -Р. 1592-1601.
54. Walker J.R. et al. Enhanced proteolytic clearance of plasma Aв by peripherally administered neprilysin does not result in reduced levels of brain Aв in mice // J. Neurosci. -2013. - № 33. - Р. 2457-2464.
55. Xia W., Wong S.T., Hanlon E. & Morin P. r-Secretase modulator in Alzheimer's disease: shifting the end // J. Alzheimers. Dis. - 2012. - № 31. - Р. 685-696.
Review
For citations:
Rodin D.I., Schvarzman A.L., Saranzeva S.V. Modern approach in the therapy of Alzheimer's disease. The Scientific Notes of the Pavlov University. 2014;21(1):6-10. (In Russ.) https://doi.org/10.24884/1607-4181-2014-21-1-6-10
Views:
1073
Email this article 